Document is current
Any future updates will be listed below
-
Authors
Trautmannsberger, Ilona https://orcid.org/0000-0002-9996-6117
Bösl, Sabina https://orcid.org/0000-0002-6011-9332
Adamek, Ina https://orcid.org/0009-0004-9614-1058
Apfelbacher, Christian https://orcid.org/0000-0003-3805-8219
Beutels, Philippe https://orcid.org/0000-0001-5034-3595
Essers, Brigitte
Ravens-Sieberer, Ulrike https://orcid.org/0000-0002-2031-095X
Weil-Olivier, Catherine https://orcid.org/0000-0001-5271-1945
Nenna, Raffaella https://orcid.org/0000-0001-8880-3462
Wetzke, Martin
Mader, Silke https://orcid.org/0000-0002-3396-0177
Tischer, Christina https://orcid.org/0000-0001-6699-9484
Zimmermann, Luc J. I. https://orcid.org/0000-0002-1409-3821
,
Bohlin, Kajsa
Bont, Louis
De Luca, Daniele
Eglin, Katarina
Esposito, Susanna
Midulla, Fabio
Nenna, Raffaella
Plagg, Barbara
Reynaud, Audrey
Rombo, Karl
Silfverdal, Sven Arne
Weil-Olivier, Catherine
Wellmann, Sven
Wetzke, Martin
Apfelbacher, Christian
Beutels, Philippe
Essers, Brigitte
Ravens-Sieberer, Ulrike
- License Information
-
More Information
Article History
Received: 21 May 2025
Accepted: 15 July 2026
First Online: 24 July 2026
Declarations
Ethics approval and consent to participate: Prior to the start of the recruitment, the Ethical Committee of the University of Maastricht in the Netherlands officially waived the need for ethics approval of the ResQ Family study as the Medical Research Involving Human Subjects Act (WMO) did not apply to the study (reference number METC 2022–3307). After confirmation of ethical clearance, the study was registered at clinicaltrials.gov (ID: NCT05550545). Data is collected, processed and stored in accordance with the General Data Protection Regulation and the Declaration of Helsinki. Informed consent was obtained from all respondents by checking a confirmation box before filling out the questionnaire.
Consent for publication: Not applicable.
Competing interests: CA received institutional funding from the Dr Wolff Group and Bionorica SE, and consultancy fees from the Dr Wolff Group, Bionorica SE, Sanofi, Incyte Biosciences, RHEACELL and LEO Pharma for services outside the submitted work. PB reports unrestricted grants from IMI (joint public-private partnership projects of the European Union) Respiratory Syncytial Virus Consortium in Europe (RESCEU) and Preparing for RSV immunisation and surveillance in Europe (PROMISE) for related work, and grants from Pfizer and Merck for unrelated work, with all payments received by his employer, the University of Antwerp. CA, PB, BE, URS, CWO, RN and MW and the PEG and ESAB members received a compensation fee from EFCNI for consulting services associated with the current study. IT, SB, IA, SM, LJIZ and CT declare that they have no competing interests.
